SENEXON-S is a Oral Tablet, Coated in the Human Otc Drug category. It is labeled and distributed by Ncs Healthcare Of Ky, Inc Dba Vangard Labs. The primary component is Docusate Sodium; Sennosides A And B.
| Product ID | 0615-8083_2f7a9208-3925-4cf7-9a22-0d9b702eb344 |
| NDC | 0615-8083 |
| Product Type | Human Otc Drug |
| Proprietary Name | SENEXON-S |
| Generic Name | Docusate Sodium -sennosides |
| Dosage Form | Tablet, Coated |
| Route of Administration | ORAL |
| Marketing Start Date | 2011-03-16 |
| Marketing End Date | 2020-08-31 |
| Marketing Category | OTC MONOGRAPH NOT FINAL / OTC MONOGRAPH NOT FINAL |
| Application Number | part334 |
| Labeler Name | NCS HealthCare of KY, Inc dba Vangard Labs |
| Substance Name | DOCUSATE SODIUM; SENNOSIDES A AND B |
| Active Ingredient Strength | 50 mg/1; mg/1 |
| NDC Exclude Flag | N |
| Marketing Start Date | 2016-12-20 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | OTC MONOGRAPH NOT FINAL |
| Application Number | part334 |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 2016-12-20 |
| Marketing End Date | 2020-08-31 |
| Ingredient | Strength |
|---|---|
| DOCUSATE SODIUM | 50 mg/1 |
| SPL SET ID: | baace5c9-ac2b-4f12-b4e7-e396dd8238f0 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0536-1247 | Senexon-S | Docusate Sodium 50mg and Sennosides 8.6mg |
| 0536-4086 | SENEXON-S | DOCUSATE SODIUM -SENNOSIDES |
| 0615-7773 | SENEXON-S | docusate sodium-sennosides tablet |
| 0615-8083 | SENEXON-S | DOCUSATE SODIUM -SENNOSIDES |
| 0615-8331 | Senexon-S | Docusate Sodium 50mg and Sennosides 8.6mg |
| 33261-749 | SENEXON-S | DOCUSATE SODIUM -SENNOSIDES |
| 52959-675 | SENEXON-S | DOCUSATE SODIUM -SENNOSIDES |
| 68788-9407 | SENEXON-S | DOCUSATE SODIUM -SENNOSIDES |
| 43063-818 | Docusate Sodium with Sennosides | DOCUSATE SODIUM -SENNOSIDES |